NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2400 participants.

Also called NCT02817360

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,400 participants (planned count) (from the registry)
Sponsor
Martin Huelsmann (from the registry)
Registry
  • NCT NCT02817360
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Austria, Netherlands, New Zealand, Spain, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT02817360. Randomized; no masking; primary purpose treatment. Start 2016-02 (registry gives no type); primary completion 2025-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients
Condition
Heart Diseases
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
RAS-antagonist and beta-blocker up-to maximal dosages
Intervention (Other)
RAS-antagonist and beta-blocker none or at stable dose
Lead sponsor
Martin Huelsmann (class: other)

Record details

Record id
cardio:ct-nct02817360
Content hash
423f6df216a3a37bee65091406195a338b04f9d776847a86d55402e6deabb9e9